2022 Volume 21 Issue 2 Pages 79-85
The effectiveness, safety, and patients’satisfaction of sofpironium bromide treatment was investigated in 46 patients with primary axillary hyperhidrosis with a baseline hyperhidrosis disease severity scale (HDSS) score of 3 or 4. The placebo consisted of a phase 3 confirmatory study of sofpironium bromide. We obtained HDSS score, visual analogue scale (VAS) for sweating, and dermatology life quality index (DLQI), and performed a patient questionnaire survey for evaluating patients’satisfaction before treatment and at 4 weeks of treatment. The proportion of patients who achieved an HDSS score of 1or 2 at 4 weeks of treatment was 82.6% (38/46 patients), which was significantly higher than 41.2% (56/136 patients) in the placebo group. Mean VAS for sweating (± standard deviation) was 7.3±1.7 before the treatment versus 4.2±2.5 at 4 weeks of the treatment,and mean DLQI total score was 6.5±5.4 before the treatment versus 2.3±2.9 at 4 weeks of the treatment, showing significant improvement for both scores. A total of 95.7% of patients (44/46 patients) continued topical therapy of sofpironium bromide. The questionnaire survey for evaluating patients’satisfaction revealed that 58.7% (27/46 patients) reported being“very satisfied”and “moderately satisfied”. As for the timing of effectiveness onset, 67.4% (31/46 patients) reported that sofpironium bromide was effective within 1week of the initiating treatment. As for benefits of this therapy, 60.9% (28/46) of the patients reported that treatment could be administered simply by topical application. The rapid resolution of hyperhidrosis and the convenience of the treatment may have contributed to the high patients’satisfaction. Skin Research, 21 :79-85, 2022
